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Inhibitors of apoptosis proteins (IAPs) are important regulators of both cell death and inflammation. In this
issue of Immunity, Vince et al. (2012) report that inhibition of IAPs results in the processing and secretion
of IL-1b through RIP3-mediated caspase-1- and caspase-8-dependent pathways.The inhibitors of apoptosis proteins
(IAPs), such as XIAP, cIAP1, and cIAP2,
play critical functions in regulating both
apoptotic cell death and inflammatory
pathways. XIAP, cIAP1, and cIAP2 con-
tain three N-terminal baculovirus IAP
repeat (BIR) domains, an ubiquitin-asso-
ciated domain, and aC-terminal RINGdo-
main that possesses ubiquitin-E3 ligase
activity (Lopez and Meier, 2010). In addi-
tion, cIAP1 and cIAP2 also contain a
central caspase recruitment domain
(CARD), which provides autoinhibition
of their E3 ligase activity. Mammalian
XIAP can effectively inhibit caspase-3, -7,
and -9 through direct interaction. In con-
trast to XIAP, cIAP1 and cIAP2 are ineffi-
cient at directly inhibiting caspase activity
(Broemer and Meier, 2009). cIAP1 and
cIAP2 are, however, capable of promoting
NF-kB activation and prosurvival signals
by K63-linked polyubiquitination of re-
ceptor interacting protein 1 (RIP1) after
engagement of tumor necrosis factor
receptor 1 (TNFR1) by TNF-a. cIAP1 and
cIAP2 also function to regulate the nonca-
nonical NF-kB pathway by inducing the
K48-linked degradative ubiquitination of
the NF-kB-inducing kinase (NIK) (Lopez
and Meier, 2010).
In addition to their role in regulating
cell survival, IAPs also have important
functions in innate immunity. Similar to
the role of cIAP1 and cIAP2 in the non-
canonical NF-kB pathway, cIAP1 and
cIAP2 regulate the MyD88-dependent
activation of MAP kinase signaling and
the production of proinflammatory cyto-
kines after Toll-like receptor 4 (TLR4)
activation by mediating the degradative
K48-linked polyubiquitination of TRAF3
(Tseng et al., 2010). cIAPs regulate anti-
viral inflammatory responses driven bythe cytosolic dsRNA receptor RIG-I, again
by targeting TRAF3 for degradative ubiq-
uitination (Mao et al., 2010). IAPs are
also required for proinflammatory cyto-
kine production by the NLR family
members NOD1 and NOD2 through
nondegradative ubiquitination of RIP2
(Bertrand et al., 2009). The precise mech-
anism of XIAP modulation of NOD
signaling remains unclear (Krieg et al.,
2009). In this issue of Immunity, Vince
et al. (2012) demonstrate that inhibition
of XIAP, cIAP1, and cIAP2 results in the
generation of IL-1b by both the NLRP3-
caspase-1 inflammasome and the acti-
vation of caspase-8. Interestingly, these
studies uncovered a unique role for RIP3
in this process.
To determine whether IAPs exert an
effect on caspase-1 activation and IL-1b
processing and secretion, the authors first
employed the use of the smac-mimetic
compound A. Smac mimetics are syn-
thetic antagonists of IAPs based on the
structure of the endogenous IAP inhibitor
Smac (second mitochondrial activator
of caspases; also known as Diablo);
compound A promotes the rapid degra-
dation of cIAP1 and cIAP2 and also
antagonizes XIAP. Treatment of murine
bone marrow-derived macrophages and
dendritic cells, after priming with either
TLR agonists or TNF-a, with compound
A resulted in the activation of caspase-1
with the subsequent processing and
secretion of IL-1b. Consistent with
these findings, macrophages genetically
deficient for XIAP, cIAP1, and cIAP2
efficiently activated caspase-1 in re-
sponse to LPS-priming alone. Impor-
tantly, the inhibition of all three IAPs was
necessary for achieving enhanced cas-
pase-1 activity. Furthermore, use ofImmunity 36,macrophages deficient in components of
the NLRP3 inflammasome demonstrated
that compound A-induced IL-1b process-
ing and secretion was only partially
dependent on caspase-1 and the NLRP3
inflammasome.
Given that compound A-induced IL-1b
processing and secretion was only
partially dependent on the NLRP3 inflam-
masome, Vince et al. (2012) examined
whether RIP1 or RIP3 were involved in
this process. Depletion of IAPs has
recently been shown to induce the forma-
tion of a RIP1-FADD-caspase-8-cFLIP
complex termed the ‘‘ripoptosome’’
(Feoktistova et al., 2011; Tenev et al.,
2011). The ripoptosome can trigger RIP3
signaling as well as activate caspase-8.
The use of RIP3-deficient macrophages
showed that both caspase-1-dependent
and caspase-1-independent IL-1b secre-
tion in response to compound A are
dependent upon the presence of RIP3.
However, the regulation of NLRP3 inflam-
masome activation byRIP3was restricted
to the smac-mimetic compound A given
that other NLRP3 agonists, such as ATP
and Alum, were fully capable of activating
caspase-1 even in the absence of RIP3. In
contrast to RIP3, inhibition of RIP1 with
Necrostatin-1 did not affect compound
A-induced IL-1b secretion. The finding
that RIP1 appears to be dispensable for
compound A-induced IL-1b secretion
indicates that further evaluation of the
role of the ripoptosome in this process is
required.
Further evaluation revealed that the
caspase-1-independent IL-1b secretion
induced by compound A was mediated
by caspase-8. Using shRNA knockdown
of caspase-8 in both C57BL6 v-myc/v-
raf immortalized macrophages and theFebruary 24, 2012 ª2012 Elsevier Inc. 155
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Figure 1. Positive and Negative Regulation of IL-1b Processing by IAPs
As shown on the left, Vince et al. (2012) demonstrate that inhibition of XIAP, cIAP1, and cIAP2 with the
smac-mimetic compound A results in RIP3 signaling. RIP3 induces the generation of mitochondrial
ROS, which is involved in activation of both the NLRP3 inflammasome as well as caspase-8. Activation
of caspase-1 and caspase-8 in turn results in the processing and secretion of IL-1b. As shown on the right,
Labbe´ et al. (2011) demonstrate that cIAP1 and cIAP2 along with TRAF2 directly interact with caspase-1
andmediate its nondegradative K63-linked polyubiquitination. Depletion of cIAP1 and cIAP2 by the smac-
mimetic BV6 results in inefficient inflammasome assembly with a resultant inhibition of IL-1b secretion.
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(both of which have defects in inflamma-
some activation), Vince et al. (2012)
demonstrated that reduction of caspase-
8 results in diminished IL-1b secretion in
response to compound A. Previously,
caspase-8 has been shown to be capable
of processing pro-IL-1b into its mature
17 kDa fragment (Maelfait et al., 2008),
further supporting a role for caspase-8 in
the observed caspase-1-independent
IL-1b maturation. The fact that RIP3-defi-
cient macrophages have further dimin-
ished compound A-induced IL-1b secre-
tion compared to caspase-1-deficient
macrophages suggests that RIP3 plays
an essential role upstream of both
caspase-1 and caspase-8. Hence, it was
surprising that compound A induced the
processing and activation of caspase-8
even in the absence of RIP3; however,
the modification of caspase-8 by com-
pound A did appear to involve RIP3.
Although ubiquitination of caspase-8 has
been suggested to be required for optimal
caspase-8 activity, additional studies are
required to define the nature of the RIP3-
mediated modification of caspase-8.
In a separate study in Immunity, Labbe´
et al. (2011) also examined the role of IAPs
in caspase-1 activation. In marked
contrast to Vince et al. (2012), this study
found that deficiency for either cIAP1 or156 Immunity 36, February 24, 2012 ª2012 EcIAP2 resulted in impaired caspase-1
activation. Using a cell-free system in
which the inflammasome is spontane-
ously activated, Labbe´ et al. (2011)
demonstrated that depletion of cIAP2
with either cIAP2 antibodies, with the
smac-mimetic BV6, or utilizing macro-
phages from cIAP2 (Birc3)-deficient mice
resulted in diminished caspase-1 activa-
tion and IL-1b processing. Consistent
with these findings, siRNA-mediated
depletion of cIAP1, cIAP2, or the adaptor
TRAF2 likewise resulted in diminished
caspase-1 activation and IL-1b process-
ing in the cell-free system. Macrophages
deficient in cIAP2 were also found to
have diminished caspase-1 activation
and IL-1b secretion in response to both
NLRP3 and NLRC4 inflammasome
agonists. Similarly cIAP1 (Birc2)- and
cIAP2-deficient mice had blunted inflam-
matory responses in vivo to the NLRP3 in-
flammasome agonists monosodium urate
and alum. Interestingly, cIAP1, cIAP2, and
TRAF2 were found by immunoprecipita-
tion to directly interact with caspase-1
and mediated its nondegradative K63-
linked polyubiquitination.
Taken together, the studies by Vince
et al. (2012) and Labbe´ et al. (2011)
demonstrate that IAPs play critical roles
in both positively and negatively regu-
lating caspase-1 activation. Althoughlsevier Inc.cIAP1 and cIAP2 are not essential for in-
flammasome activation, Labbe´ et al.
(2011) suggest that they along with
TRAF2 aid in inflammasome activation
possibly through providing the appro-
priate polyubiquitination modifications of
caspase-1 that may allow it to more effec-
tively assemble NLRP3 and NLRC4 in-
flammasome complexes (Figure 1). Vince
et al. (2012) also show a role for IAPs in
caspase-1 activation, but in contrast to
Labbe´ et al. (2011) they found that deple-
tion of XIAP, cIAP1, and cIAP2 leads to
RIP3-dependent generation of reactive
oxygen species that subsequently results
in caspase-1 activation as part of the
NLRP3 inflammasome (Figure 1). Clearly,
further studies will be required to recon-
cile these two apparently discrepant roles
of IAPs in caspase-1 activation. However,
given the diverse roles of IAPs it may be
very possible that cIAP1 and cIAP2 may
be functioning directly at the level of
caspase-1 modification while at the
same time XIAP, cIAP1, and cIAP2 are
holding RIP3 in check. Regardless of the
pro- or anti-inflammatory roles of IAPs, it
is essential that we better understand
the inflammatory consequences of IAP
inhibition by smac mimetics given their
potential therapeutic usages in malig-
nancy. The use of smac mimetics by
Vince et al. (2012) has also uncovered an
interesting alternate pathway leading to
IL-1b processing and secretion involving
RIP3 and caspase-8 (Figure 1). The find-
ing that RIP3-driven reactive oxygen
species production can induce caspase-
8 activation provides a tempting mecha-
nism to explain a variety of disease
models in which IL-1b processing
appears to be occurring independently
of caspase-1.REFERENCES
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SOCS1 and SOCS3 are specific inhibitors for JAK tyrosine kinases. In this issue of Immunity, Babon et al.
(2012) discovered the inhibition mechanism of SOCS3 by employing nuclear magnetic resonance and
classical enzyme kinetics.Janus kinase (JAK), which is a key signal
transmitter of cytokines, has been shown
to be an attractive therapeutic target for
cancer and inflammatory diseases. Most
cytokines, including interleukins, inter-
ferons (IFNs), and hematopoietic growth
factors, activate JAKs. In mammals, the
JAK family comprises four members:
JAK1, JAK2, JAK3, and TYK2. JAK1,
JAK2, andTYK2appear to be ubiquitously
expressed, whereas JAK3 expression is
normally limited to hematopoietic cells.
Activated JAKs phosphorylate the asso-
ciated receptor cytoplasmic domains,
which then creates docking sites for
SH2-containing signaling proteins, includ-
ing signal transducers and activators of
transcription (STATs). The Ras-ERK and
PI3 kinase pathways are also activated
through JAKs. Aberrant activation of these
pathways is often observed in many
cancer and leukemic cells. Hyperactiva-
tion of the JAK-STAT pathway plays a
role in several immunological disorders
such as inflammatory diseases, autoim-
mune diseases, and allergy.
Several JAK2 inhibitors are under
development for the treatment of myelo-
proliferative neoplasias (MPN) and other
tumors. This is because constitutive acti-
vation of JAK2 was found in leukemias
and lymphomas (via formation of chi-meric proteins) and in MPN (via a
V617F mutation). JAK inhibitors are also
effective for tumors with constitutive
JAK-STAT pathway activation without
mutations. Therapeutic benefit from JAK
kinase inhibition has already been estab-
lished in rheumatoid arthritis (RA) with
the use of CP-690,550 (Tofacitinib), a
pan-JAK inhibitor. CP-690,550 was orig-
inally intended for organ transplantation
immunosuppression because it is a
potent inhibitor of JAK3, but has also
shown to have activity against JAK1
and JAK2. More recently, the selective
JAK1, JAK2 inhibitor, INCB028050, has
demonstrated efficacy in various rodent
models of RA, further demonstrating the
central role JAK kinases play in this
disease.
There is a natural inhibitor family for the
JAKs: the SOCS family of proteins (Alex-
ander and Hilton, 2004; Yoshimura et al.,
2007). Overexpression of these proteins
has been shown to effectively suppress
tumors and RA models (Yoshimura et al.,
2007). Thus, SOCS mimetics is a strategy
for developing therapeutics to these
diseases. However, a precise mechanism
of how SOCS inhibits JAK kinase activity
remains to be established. In this issue
of Immunity, Babon et al. (2012) suc-
ceeded in obtaining NMR spectrums ofJAK2 kinase domain and the SOCS3
complex, and, in combination with clas-
sical biochemical enzyme assays, they
discovered an unexpected mechanism
through which SOCS3 inhibits JAK kinase
activity.
The suppressor of cytokine signaling
(SOCS) protein family comprises eight
members (cytokine-inducible SH2 protein
[CIS] and SOCS1–SOCS7). The central
SH2 domain determines the target of
each SOCS and CIS protein. There is
a conserved sequence called extended
SH2 domain (ESS) adjacent to the SH2
domain, which is necessary for a high-
affinity binding of the SH2 domain to
the target phosphopeptides (Babon
et al., 2006; Yasukawa et al., 1999). The
SH2 domain (including ESS) of SOCS1
directly binds to the activation loop of
JAK (Yasukawa et al., 1999). While the
SH2 domains of CIS, SOCS2, and
SOCS3 bind to phosphorylated tyrosine
residues on activated cytokine receptors,
SOCS3 binds to gp130-related cytokine
receptors, including the phosphorylated
tyrosine 757 (Y757) residue of gp130, the
Y800 residue of IL-12 receptor b2, and
Y985 of the leptin receptor, showing that
suppression by SOCS3 is relatively
specific to STAT3 and STAT4. SOCS3
does not inhibit IL-10-mediated STAT3February 24, 2012 ª2012 Elsevier Inc. 157
